Dr. Lindsay Rein is an Associate Professor of Medicine in the Division of Hematologic Malignancies and Cellular Therapy at Duke University. She earned her M.D. from the University of North Dakota School of Medicine and Health Sciences and went on to complete both her Internal Medicine residency training as well as her Hematology and Medical Oncology fellowship training at Duke before joining the faculty in 2014.  Dr. Rein has a specific research interest in the development of novel therapies for patients with myeloproliferative neoplasms (MPNs). She sees patients with various myeloproliferative disorders including systemic mastocytosis (SM), chronic myeloid leukemia (CML), primary myelofibrosis (PMF), essential thrombocytosis (ET) and polycythemia vera (PV) and leads a large program of both early and late phase clinical trials at Duke for these patients. She is a panel member for the NCCN guidelines for MPNs, Systemic Mastocytosis, and Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes and is also a member of the H Jean Khoury Cure CML Consortium.